KalVista Pharmaceuticals, Inc. — fact timeline

KalVista Pharmaceuticals, Inc. entered into Agreement and Plan of Merger with Chiesi Farmaceutici S.p.A. valued at $27.00 per Share (effective 2026-04-29).

“On April 29, 2026, KalVista Pharmaceuticals, Inc., a Delaware corporation (the " Company "), entered into an Agreement and Plan of Merger (the " Merger Agreement "), by and among the Company, Chiesi Farmaceutici S.p.A., an Italian società per azioni (" Parent "), Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (" Purchaser "), and KalVista Pharmaceuticals Limited, a private limited company organized under the laws of England and Wales.”

KalVista Pharmaceuticals, Inc. incurred convertible notes of $143.75 million in aggregate principal amount with Initial Purchasers at 3.250% maturing due 2031.

“On September 29, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) completed its previously announced sale of $143.75 million in aggregate principal amount of its 3.250% Convertible Senior Notes due 2031”

Jebediah T. Ledell resigned as Chief Operating Officer at KalVista Pharmaceuticals, Inc..

“On May 12, 2025, Jebediah T. Ledell notified KalVista Pharmaceuticals, Inc. (the “Company”) of his decision to resign from his position as Chief Operating Officer of the Company, effective immediately.”

Brian Piekos was appointed as Chief Financial Officer at KalVista Pharmaceuticals, Inc..

“Effective September 9, 2024, the Board of Directors (the “Board”) of KalVista Pharmaceuticals, Inc. (the “Company”) appointed Brian Piekos as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.”

William Fairey was appointed as Class III Director at KalVista Pharmaceuticals, Inc..

“the Board approved the appointment of William Fairey (“ Mr. Fairey ”) to the Board effective immediately, to serve until his successor is duly elected and qualified”